Debora Wanner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Debora Wanner has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Melanie Generali
Institute for Regenerative Medicine (IREM) University of Zurich Schlieren 8952 Switzerland
2 shared publications - Beat W. Schaefer
Department of Hematology, University Hospital, Zurich, Switzerland
1 shared publication - Benedikt Weber
Department of Dermatology, Medical University of Vienna, Vienna, Austria
1 shared publication - Debora Kehl
Institute for Regenerative Medicine (IREM), Center for Therapy Development and Good Manufacturing Practice, University of Zurich, Zurich, Switzerland
1 shared publication - Elisa A. Casanova
Division of Trauma Surgery, Center for Clinical Research, University Hospital Zurich, University of Zurich, Zurich, Switzerland
1 shared publication - Elisa A. Casanova
Division of Trauma Surgery, Center for Clinical Research, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland
1 shared publication
Latest Publications
- Open Access
High Frequency of Tumor Propagating Cells in Fusion-Positive Rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Fusion-positive RMS (FPRMS), expressing the PAX3/7-FOXO1, has a worse prognosis compared to the more common fusion-negative RMS (FNRMS). Although several studies reported hierarchical organization for FNRMS with the identification of cancer stem cells, the cellular organization of FPRMS is not yet clear. In this study we investigated the expression of key stem cell markers, developed a sphere assay, and investigated the seven most common FPRMS cell lines for subpopulations of tumor propagating cancer stem-like cells, also called cancer stem cells (CSCs). Moreover, loss- and gain-of-functions of the stem cell genes SOX2, OCT4, and NANOG were investigated in the same cells. Single-cell clonal analysis was performed in vitro as well as in vivo. We found that no stable CSC subpopulation could be enriched in FPRMS. Unlike depletion of PAX3-FOXO1, neither overexpression nor siRNA-mediated downregulation of SOX2, OCT4, and NANOG affected physiology of RMS cells. Every single subclone-derived cell clone initiated tumor growth in mice, despite displaying considerable heterogeneity in gene expression. FPRMS appears to contain a high frequency of tumor propagating stem-like cells, which could explain their higher propensity for metastasis and relapse. Their dependency on PAX3-FOXO1 activity reinforces the importance of the fusion protein as the key therapeutic target.
Open AccessHigh Frequency of Tumor Propagating Cells in Fusion-Positive Rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Fusion-positive RMS (FPRMS), expressing the PAX3/7-FOXO1, has a worse prognosis compared to the more common fusion-negative RMS (FNRMS). Although several studies reported hierarchical organization for FNRMS with the identification of cancer stem cells, the cellular organization of FPRMS is not yet clear. In this study we investigated the expression of key stem cell markers, developed a sphere assay, and investigated the seven most common FPRMS cell lines for subpopulations of tumor propagating cancer stem-like cells, also called cancer stem cells (CSCs). Moreover, loss- and gain-of-functions of the stem cell genes SOX2, OCT4, and NANOG were investigated in the same cells. Single-cell clonal analysis was performed in vitro as well as in vivo. We found that no stable CSC subpopulation could be enriched in FPRMS. Unlike depletion of PAX3-FOXO1, neither overexpression nor siRNA-mediated downregulation of SOX2, OCT4, and NANOG affected physiology of RMS cells. Every single subclone-derived cell clone initiated tumor growth in mice, despite displaying considerable heterogeneity in gene expression. FPRMS appears to contain a high frequency of tumor propagating stem-like cells, which could explain their higher propensity for metastasis and relapse. Their dependency on PAX3-FOXO1 activity reinforces the importance of the fusion protein as the key therapeutic target.
- Open Access
- 1 October 2019
- Published by Elsevier in Acta Biomaterialia
- Vol. 97, 333-343
Autologous endothelialized small-caliber vascular grafts engineered from blood-derived induced pluripotent stem cells
- 1 October 2019
- Published by Elsevier in Acta Biomaterialia
- Vol. 97, 333-343
Open AccessAutologous endothelialized small-caliber vascular grafts engineered from blood-derived induced pluripotent stem cells